SCANDIUM II Trial - A Phase I Randomized Controlled Multicentre Trial of Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Melphalan
- Indications Liver metastases; Uveal melanoma
- Focus Adverse reactions
- Acronyms SCANDIUM II
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 20 Nov 2023 Planned End Date changed from 1 Sep 2023 to 1 Dec 2024.
- 20 Nov 2023 Planned primary completion date changed from 10 Aug 2023 to 4 Aug 2024.